Delcath Systems, Inc. Announces Extension of Expiration Date of its Consent Solicitation and Ability to Change Consent Once V...
August 22 2017 - 8:30AM
Delcath Systems, Inc. (NASDAQ:DCTH) (the “Company”) announced today
that the deadline for its current Consent Solicitation (the
“Consent Solicitation”), currently set to expire at 5:00 p.m.
Eastern Time, on August 28, 2017, has been extended until September
7, 2017 at 5:00 p.m. Eastern Time to allow more opportunity for
stockholders to submit consents on the proposal described in the
Company’s definitive proxy statement filed with the Securities and
Exchange Commission on July 26, 2017, which is a proposal to
approve an amendment to its amended and restated certificate of
incorporation to effect a reverse stock split of its common stock,
which the Company believes is vitally important to the Company’s
future. The Company also announced that stockholders, who
have previously submitted a consent, may choose to change their
vote by submitting a new consent on or before the extended
September 7, 2017 deadline.
The record date for the Consent Solicitation
remains July 13, 2017. Stockholders who have previously
submitted their proxy or otherwise voted and who do not want to
change their vote need not take any action. Company stockholders as
of the July 13, 2017 record date can submit consents, even if they
have subsequently sold their shares. The Company’s board of
directors and management respectfully request all such holders as
of the record date to please submit your consents as soon as
possible.
No changes have been made in the proposal for
which consent is solicited in the Consent Solicitation. THE COMPANY
STRONGLY ADVISES ALL OF ITS STOCKHOLDERS TO READ THE PROXY
STATEMENT AND OTHER PROXY MATERIALS RELATING TO THE ANNUAL MEETING
BECAUSE THEY CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS
ARE AVAILABLE AT NO CHARGE ON THE SECURITIES AND EXCHANGE
COMMISSION’S WEBSITE AT WWW.SEC.GOV. In addition, copies of the
Proxy Statement and other documents may be obtained free of charge
by accessing the Company’s website at www.delcath.com or by
contacting the Company’s Corporate Secretary at 212-489-2100 or by
mail to Corporate Secretary, Delcath Systems, Inc., 1633 Broadway,
Suite 22C, New York, New York 10019.
Voting Instructions
All stockholders as of the July 13, 2017 record
date can submit consents, even if they have subsequently sold their
shares, and the Company encourages stockholders to do so before
September 6, 2017 at 11:59 p.m. Eastern Time. Stockholders are
reminded that their vote is extremely important and are urged to
complete, sign, date and mail the consent card at their earliest
convenience. Any stockholder who would like to vote by telephone
may call 877-777-8133 or online by visiting www.proxyvote.com.
YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE
TODAY!
About Delcath SystemsDelcath
Systems, Inc. is an interventional oncology Company focused on
the treatment of primary and metastatic liver cancers. Our
investigational product – Melphalan Hydrochloride for Injection for
use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is
designed to administer high-dose chemotherapy to the liver while
controlling systemic exposure and associated side effects. We have
commenced a global Phase 3 FOCUS clinical trial for Patients with
Hepatic Dominant Ocular Melanoma (OM), and plans to initiate a
Registration trial for intrahepatic cholangiocarcinoma (ICC) by the
end of 2017 contingent on effecting the reverse stock split as
outlined in the Company’s consent proposal. Melphalan/HDS has not
been approved by the U.S. Food & Drug
Administration (FDA) for sale in the U.S. In Europe, our
system has been commercially available since 2012 under the trade
name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan
(CHEMOSAT), where it has been used at major medical centers to
treat a wide range of cancers of the liver.
Forward Looking
Statements:Private Securities Litigation Reform Act of
1995 provides a safe harbor for forward-looking statements made by
the Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to: the
timing and results of the Company’s clinical trials including
without limitation the OM and ICC clinical trial programs, timely
enrollment and treatment of patients in the global Phase 3 OM
clinical trial, IRB or ethics committee clearance of the Phase 3 OM
and ICC Registration trial protocols from participating sites and
the timing of site activation and subject enrollment in each trial,
the impact of the presentations at major medical conferences and
future clinical results consistent with the data presented,
approval of Individual Funding Requests for reimbursement of the
CHEMOSAT procedure, the impact, if any of ZE reimbursement on
potential CHEMOSAT product use and sales in Germany, clinical
adoption, use and resulting sales, if any, for the CHEMOSAT system
to deliver and filter melphalan in Europe including the key markets
of Germany and the UK, the Company’s ability to successfully
commercialize the Melphalan HDS/CHEMOSAT system and the potential
of the Melphalan HDS/CHEMOSAT system as a treatment for patients
with primary and metastatic disease in the liver, our ability to
obtain reimbursement for the CHEMOSAT system in various markets,,
approval of the current or future Melphalan HDS/CHEMOSAT system for
delivery and filtration of melphalan or other chemotherapeutic
agents for various indications in the U.S. and/or in foreign
markets, actions by the FDA or other foreign regulatory agencies,
the Company’s ability to successfully enter into strategic
partnership and distribution arrangements in foreign markets and
the timing and revenue, if any, of the same, uncertainties relating
to the timing and results of research and development projects, our
ability to maintain NASDAQ listing, and uncertainties regarding the
Company’s ability to obtain financial and other resources for any
research, development, clinical trials and commercialization
activities. These factors, and others, are discussed from time to
time in our filings with the Securities and Exchange Commission.
You should not place undue reliance on these forward-looking
statements, which speak only as of the date they are made. We
undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after
the date they are made.
Contact:
Scott Gordon
President - CoreIR
Email: investorrelations@delcath.com